(E)-1-(2-chlorophenyl)-3-(2,6-dichlorophenyl)prop-2-en-1-one | 1087748-79-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-(2-chlorophenyl)-3-(2,6-dichlorophenyl)prop-2-en-1-one
• 英文别名: 1-(2-chlorophenyl)-3-(2,6-dichlorophenyl)prop-2-en-1-one
• CAS: 1087748-79-5
• 化学式: C₁₅H₉Cl₃O
• 分子量: 311.595
• InChiKey: KDUCRYZJQJJHNO-CMDGGOBGSA-N

物化性质

• 沸点：
  445.6±45.0 °C(Predicted)
• 密度：
  1.380±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-1-(2-chlorophenyl)-3-(2,6-dichlorophenyl)prop-2-en-1-one 在 aluminum (III) chloride 、 palladium on activated charcoal 、 氢气 、 溴 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 生成
  参考文献：
  名称：

  2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5

  摘要：

  In our previous work, novel 2,4,5-trisubstituted thiazole derivatives (TSTs) were synthesized, and their activities were evaluated against HIV-1 reverse transcriptase. Some interesting results were obtained, which led us to a new discovery regarding these TST5. In the present study, 21 new 2,4,5-trisubstituted thiazole derivatives were rationally designed and synthesized as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) in accordance with our previous study. Among the synthesized target compounds, compounds 14, 16, 17, and 19 showed more potent inhibitory activities against HIV-1 with an IC50 value of 0.010 mu M. Compounds 4, 9, 10, 11, 13 and 16 were further tested on nine NNRTI-sresistant HIV-1 strains, and all of these compounds exhibited inhibitory effects. A molecular docking study was conducted, and the results showed a consistent and stable binding mode for the typical compounds. These results have provided deeper insights and SAR of these types of NNRTIs. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.07.047
• 作为产物：
  描述：

  邻氯苯乙酮 、 2,6-二氯苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 0.17h， 以73%的产率得到(E)-1-(2-chlorophenyl)-3-(2,6-dichlorophenyl)prop-2-en-1-one
  参考文献：
  名称：

  2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5

  摘要：

  In our previous work, novel 2,4,5-trisubstituted thiazole derivatives (TSTs) were synthesized, and their activities were evaluated against HIV-1 reverse transcriptase. Some interesting results were obtained, which led us to a new discovery regarding these TST5. In the present study, 21 new 2,4,5-trisubstituted thiazole derivatives were rationally designed and synthesized as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) in accordance with our previous study. Among the synthesized target compounds, compounds 14, 16, 17, and 19 showed more potent inhibitory activities against HIV-1 with an IC50 value of 0.010 mu M. Compounds 4, 9, 10, 11, 13 and 16 were further tested on nine NNRTI-sresistant HIV-1 strains, and all of these compounds exhibited inhibitory effects. A molecular docking study was conducted, and the results showed a consistent and stable binding mode for the typical compounds. These results have provided deeper insights and SAR of these types of NNRTIs. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.07.047

文献信息

• Small-molecule modulators of hepatocyte growth factor / scatter factor activities
  申请人：——

  公开号：US20030045559A1

  公开（公告）日：2003-03-06

  The invention is directed to small organic molecules having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer.

  该发明涉及具有模拟或激活肝细胞生长因子/散发因子（HGF/SF）活性的小有机分子，或抑制或拮抗HGF/SF活性的能力，前者可用于促进组织或器官的血管化，促进伤口或组织愈合，或增强或恢复缺血组织（例如心肌梗死后的心脏）的血流。细胞生长或增殖的抑制对于治疗炎症性疾病（如炎性关节和皮肤疾病）和增殖异常性疾病（如癌症）是有益的。
• Small-molecule modulators of hepatocyte growth factor/scatter factor activities
  申请人：Pillarisetti Sivaram

  公开号：US20050096372A1

  公开（公告）日：2005-05-05

  The invention is directed to small organic molecules having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer.

  本发明涉及具有模拟或激动肝细胞生长因子/散射因子（HGF/SF）活性，或抑制或拮抗 HGF/SF 活性的有机小分子，前者可用于促进组织或器官的血管化，以促进伤口或组织愈合，或增加或恢复缺血组织（如心肌梗塞后的心脏）的血流量。抑制细胞生长或增殖有利于治疗炎症性疾病（如关节炎和皮肤病）和增殖障碍性疾病（如癌症）等。
• MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF
  申请人：North Shore-Long Island Jewish Health System

  公开号：EP1355921A2

  公开（公告）日：2003-10-29
• HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES
  申请人：Paka Latha

  公开号：US20100256117A1

  公开（公告）日：2010-10-07

  Methods are provided for treating fibrotic connective tissue diseases such as scleroderma and conditions such as surgically-induced adhesions using compounds that activate the signaling pathways of hepatocyte growth factor.
• HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA
  申请人：Yuzhakov Alexander

  公开号：US20110230407A1

  公开（公告）日：2011-09-22

  Methods are provided for treating and preventing demyelinating diseases including multiple sclerosis, and traumatic injury to the central nervous system including brain trauma and spinal cord injury, by administering a compound or pharmaceutical composition of the invention. Useful compounds include hepatocyte growth factor/scatter factor protein, fragments, fusion polypeptides and muteins thereof, and nucleic acid and expression vectors encoding such proteins. Other useful compounds include small molecule HGF/SF agonists and mimetics.